NO20014417D0 - Vaskul¶re adhesjonsmolekyler samt modulering av deres funksjon - Google Patents

Vaskul¶re adhesjonsmolekyler samt modulering av deres funksjon

Info

Publication number
NO20014417D0
NO20014417D0 NO20014417A NO20014417A NO20014417D0 NO 20014417 D0 NO20014417 D0 NO 20014417D0 NO 20014417 A NO20014417 A NO 20014417A NO 20014417 A NO20014417 A NO 20014417A NO 20014417 D0 NO20014417 D0 NO 20014417D0
Authority
NO
Norway
Prior art keywords
adhesion molecules
modulation
function
vascular adhesion
cram
Prior art date
Application number
NO20014417A
Other languages
English (en)
Other versions
NO333085B1 (no
NO20014417L (no
Inventor
Beat Albert Imhof
Michel Aurrand-Lions
Original Assignee
Rmf Dictagene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rmf Dictagene Sa filed Critical Rmf Dictagene Sa
Publication of NO20014417D0 publication Critical patent/NO20014417D0/no
Publication of NO20014417L publication Critical patent/NO20014417L/no
Publication of NO333085B1 publication Critical patent/NO333085B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20014417A 1999-03-11 2001-09-11 Opploselig CRAM-1 polypeptid antistoff rettet mot CRAM-1 og som modulerer transendotelial migrering av leukocytter, samt anvendelse derav for fremstilling av medikamenter for inhibering av angiogenese i tumorer. NO333085B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200746 1999-03-11
PCT/EP2000/002219 WO2000053749A2 (en) 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function

Publications (3)

Publication Number Publication Date
NO20014417D0 true NO20014417D0 (no) 2001-09-11
NO20014417L NO20014417L (no) 2001-11-12
NO333085B1 NO333085B1 (no) 2013-02-25

Family

ID=8239973

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014417A NO333085B1 (no) 1999-03-11 2001-09-11 Opploselig CRAM-1 polypeptid antistoff rettet mot CRAM-1 og som modulerer transendotelial migrering av leukocytter, samt anvendelse derav for fremstilling av medikamenter for inhibering av angiogenese i tumorer.

Country Status (23)

Country Link
US (3) US7393651B2 (no)
EP (2) EP2292761A1 (no)
JP (2) JP4836329B2 (no)
CN (2) CN1637019A (no)
AT (1) ATE500328T1 (no)
AU (1) AU782139B2 (no)
BR (1) BR0008915A (no)
CA (1) CA2362896C (no)
CZ (1) CZ303128B6 (no)
DE (1) DE60045681D1 (no)
EE (1) EE05497B1 (no)
ES (1) ES2361905T3 (no)
HK (1) HK1044169A1 (no)
HU (1) HU229376B1 (no)
IL (1) IL145310A0 (no)
IS (1) IS2819B (no)
MX (1) MXPA01009110A (no)
NO (1) NO333085B1 (no)
NZ (1) NZ514091A (no)
PL (1) PL207994B1 (no)
RU (1) RU2244748C2 (no)
WO (1) WO2000053749A2 (no)
ZA (1) ZA200107283B (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
CN1637019A (zh) * 1999-03-11 2005-07-13 Rmf迪克塔吉恩有限公司 血管粘着分子及其功能的调节
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
NZ594285A (en) 2005-11-04 2013-02-22 Genentech Inc USE OF COMPLEMENT PATHWAY INHIBITOR ANTIBODY AGAINST C5a TO TREAT OCULAR DISEASES
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
CA2663243A1 (en) 2006-09-28 2008-04-03 Merck Serono S.A. Junctional adhesion molecule-c (jam-c) binding compounds and methods of their use
KR20160092061A (ko) 2006-11-02 2016-08-03 제넨테크, 인크. 인간화 항-ｄ 인자 항체
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
BRPI0815094B8 (pt) * 2007-08-06 2023-04-18 Noxxon Pharma Ag Uso de uma molécula de ácido l-nucleico ligada a sdf-1
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CR20160132A (es) 2013-08-12 2016-08-25 Genentech Inc Composiciones y método para tratar condiciones asociadas con el complemento
MX2016014160A (es) 2014-05-01 2017-02-16 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos.
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
CA2283678A1 (en) * 1997-03-14 1998-09-17 Human Genome Sciences, Inc. 28 human secreted proteins
EP0970111A2 (en) * 1997-03-21 2000-01-12 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
JP2001512014A (ja) 1997-08-01 2001-08-21 ジェンセット 脳組織から同定された分泌タンパク質の５’ｅｓｔ
US20030082540A1 (en) 1997-09-17 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
MXPA01006057A (es) * 1998-12-16 2003-09-10 Genentech Inc Polipeptidos secretados y transmembranales y acidos nucleicos que los codifican.
CN1637019A (zh) * 1999-03-11 2005-07-13 Rmf迪克塔吉恩有限公司 血管粘着分子及其功能的调节
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer

Also Published As

Publication number Publication date
JP2002537837A (ja) 2002-11-12
CN1355843A (zh) 2002-06-26
US7393651B2 (en) 2008-07-01
AU782139B2 (en) 2005-07-07
EE200100472A (et) 2002-12-16
BR0008915A (pt) 2002-04-09
US7670826B2 (en) 2010-03-02
ZA200107283B (en) 2002-12-24
CN100469878C (zh) 2009-03-18
EP2292761A1 (en) 2011-03-09
AU4105100A (en) 2000-09-28
WO2000053749A3 (en) 2000-12-14
CN1637019A (zh) 2005-07-13
RU2244748C2 (ru) 2005-01-20
US20050266426A1 (en) 2005-12-01
US20100267649A1 (en) 2010-10-21
EP1163337B1 (en) 2011-03-02
IL145310A0 (en) 2003-01-12
NO333085B1 (no) 2013-02-25
JP4836329B2 (ja) 2011-12-14
IS2819B (is) 2012-12-15
HU229376B1 (en) 2013-11-28
NO20014417L (no) 2001-11-12
NZ514091A (en) 2004-01-30
HK1044169A1 (en) 2002-10-11
WO2000053749A2 (en) 2000-09-14
ATE500328T1 (de) 2011-03-15
CZ20013267A3 (cs) 2002-02-13
PL207994B1 (pl) 2011-02-28
EP1163337A2 (en) 2001-12-19
CA2362896A1 (en) 2000-09-14
HUP0200606A3 (en) 2004-11-29
CZ303128B6 (cs) 2012-04-18
US8143056B2 (en) 2012-03-27
MXPA01009110A (es) 2002-08-20
PL350417A1 (en) 2002-12-16
IS6072A (is) 2001-09-10
EE05497B1 (et) 2011-12-15
US20080274970A1 (en) 2008-11-06
CA2362896C (en) 2012-07-31
JP2010233572A (ja) 2010-10-21
ES2361905T3 (es) 2011-06-24
HUP0200606A2 (en) 2002-06-29
DE60045681D1 (de) 2011-04-14

Similar Documents

Publication Publication Date Title
NO20014417L (no) Vaskul¶re adhesjonsmolekyler samt modulering av deres funksjon
PT1132403E (pt) Peptidos inibidores de tgf g beta1
DE69333348D1 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten
ATE280826T1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
DE69940888D1 (de) Copolymer-1-verwandte polypeptide für die verwendung als molekulargewichtsmarker und zur therapie
EE9800306A (et) Isoleeritud dimeerne fibroblastide aktivatsioonivalk alfa ja selle kasutusalad
DE69518760D1 (de) Wachstumsdifferenzierungsfaktor-12
DE69312232D1 (de) Bpc-peptide, ihre herstellung und verwendung
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
DK226889D0 (da) Alkoholpeptidderivat samt anvendelse deraf til mindskning af blodkoagulation
DE59002772D1 (de) Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms.
ATE123942T1 (de) 5-aryl-3h-1,2,4-triazol-3-one und ihre verwendung als antikonvulsiva.
ATE308616T1 (de) Rantes mutanten und deren therapeutische verwendungen
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
ATE390440T1 (de) Neuroaktive peptide
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
BR0007816A (pt) Fator de estimulação óssea
DE69836278D1 (de) Allele formen von menschlichem stat3
DE69530600D1 (de) Verwendung von nk1-rezeptor antagonisten zur zubereitung von arzneimitteln mit kardioregulierender wirkung
Burnyasheva et al. On the question of the treatment of urticaria
IT1241456B (it) Associazione medicamentosa per il trattamento dell'ipertensione e dell'insufficienza cardiaca congestiva. (caso 100-7516)
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.
NO940797L (no) Reseptorderivater som har bindingseter for human-rhinovirus

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees